120
Participants
Start Date
June 30, 2009
Primary Completion Date
August 31, 2010
Study Completion Date
August 31, 2010
IMVAMUNE
Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
IMVAMUNE
One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
University of Rochester, Medical Center, Rochester
Orlando Clinical Research Center, Orlando
University of Iowa, Iowa City
University of Kentucky, School of Medicine, Department of Medicine, Lexington
Lead Sponsor
Bavarian Nordic
INDUSTRY